Pharmaceuticals News and Research

RSS

Reese Pharmaceutical chooses SYSPRO ERP for private labeling and distribution operations

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that Reese Pharmaceutical Company has selected SYSPRO ERP (Enterprise Resource Planning) software to run its private labeling and distribution operations. Reese, based in Cleveland, Ohio, has been in business for more than a century.

19 Mar 2010

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma Incorporated today announced the presentation of two abstracts relating to Cinryze™ (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.

19 Mar 2010

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Richard S. Rofe, who serves as Managing Director for Arcadia Capital Advisors, LLC, and is part of a shareholder group that includes Arcadia with a 9.97 percent ownership interest in CPEX Pharmaceuticals, Inc.,, commented on CPEX's recent announcement of failed Phase 2a Nasulin study results.

19 Mar 2010

Valeant Pharmaceuticals International advances dermatology presence in Brazilian market

Valeant Pharmaceuticals International today announced that it has signed a binding agreement to acquire a private branded generics and over the counter company located in Brazil for approximately US$28 million. A large portion of the company's product portfolio is in dermatology and the company had annual sales of approximately US$19 million in 2009.

19 Mar 2010

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.

19 Mar 2010

Teva Pharmaceutical Industries receives right to market generic version of Schering’s Temodar

Teva Pharmaceutical Industries Ltd. announced today that the parties to the patent litigation regarding Barr’s U.S. generic version of Schering’s Temodar® have entered into an agreement pending resolution of Schering’s appeal to the Federal Circuit of the U.S. District Court’s decision holding the ‘291 Patent unenforceable.

19 Mar 2010

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2010, contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

Global initiative for reducing time taken to introduce new combination TB treatments

Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.

19 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).

19 Mar 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

VIVUS reports product revenues of $8.5M from sale of MUSE in fourth-quarter 2009

BeaconEquity.com announces an investment report featuring VIVUS Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office has granted and will reissue the composition of matter patent for picoplatin as RE41209, replacing USPN 5,665,771 ('771 patent), on April 6, 2010. The reissue was applied for May 8, 2009, and, on March 17, 2010, the USPTO released the "Issue Notification" for the reissue application.

19 Mar 2010

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.

19 Mar 2010

Astellas Pharma's proposed acquisition of OSI Pharmaceuticals: HSR waiting period expires

Astellas Pharma Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Astellas' proposed acquisition of OSI Pharmaceuticals Inc. has expired.

19 Mar 2010

W. R. Grace earns GMP certification

W. R. Grace & Co.has earned Good Manufacturing Practices certification of its facility in Baltimore, Maryland. The certification encompasses Grace’s Quality Management System that includes the standards, procedures and manufacturing operations used by the company in the production of pharmaceutical grade silica (commonly marketed by Grace under the SYLOID® brand name).

19 Mar 2010

BioSense Technologies' Z-Sense Differential Impedance Sensing diagnostic system rapidly identifies drug susceptibility

BioSense Technologies, a pioneer in the development of diagnostic systems for rapid drug susceptibility testing, announced today that it presented key scientific findings at the National Foundation for Infection Disease 2010 Annual Conference on Antimicrobial Resistance, held in Bethesda, MD in early February.

19 Mar 2010

Pharmaceuticals News and Research

Reese Pharmaceutical chooses SYSPRO ERP for private labeling and distribution operations

ViroPharma to present Cinryze data at Southern European Allergy Society congress

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Valeant Pharmaceuticals International advances dermatology presence in Brazilian market

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Teva Pharmaceutical Industries receives right to market generic version of Schering’s Temodar

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

Global initiative for reducing time taken to introduce new combination TB treatments

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

VIVUS reports product revenues of $8.5M from sale of MUSE in fourth-quarter 2009

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Astellas Pharma's proposed acquisition of OSI Pharmaceuticals: HSR waiting period expires

W. R. Grace earns GMP certification

BioSense Technologies' Z-Sense Differential Impedance Sensing diagnostic system rapidly identifies drug susceptibility

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence